Improving specificity, destroying the ability to transport to tumors, maintaining low toxicity, and stabilizing serum are key challenges when employing antimicrobial peptides to treat breast cancer
Easy measuring: At 166.7 mg/mL, 1 unit = 0.01 mL = 1.67 mg on a U100 insulin syringe
Accepted diagnoses include pernicious anemia (D51.0), documented malabsorption conditions, and confirmed B12 deficiency (E53.8)
A Vitamin D Injection ensures rapid absorption and can help address deficiencies that lead to fatigue, low immunity, or bone weakness
TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
Boosts Energy Levels One of the most well-known benefits of B12 injections is their ability to boost energy
